Detecting Minimal Residual Disease in Neuroblastoma: Still a Ways to Go

Detecting minimal residual disease in neuroblastoma: still a ways to go.

Neuroblastoma is the most common extracranial solid tumor of childhood and accounts for 10% of all cancers in children. The development of neuroblastoma involves both embryonic and tumorigenic factors, making the tumor very heterogeneous both biologically and clinically. Neuroblastoma tumors originate from embryonic neural crest cells committed to the development of the sympathetic nervous syst...

Chronic Obstructive Pulmonary Disease: Reduced Nihilism, But There is Still a Ways to Go.

Abbreviations: chronic obstructive pulmonary disease, COPD; quality adjusted life years, QALYs; forced expiratory volume in 1 second, FEV1; forced vital capacity, FVC Citation: Pinnock H, Sohanpal R. Editorial-Chronic obstructive pulmonary disease: reduced nihilism, but there is still a ways to go. Chronic Obstr Pulm Dis (Miami). 2016; 3(3): 605-609. doi: http://dx.doi.org/10.15326/jcopdf.3.3.2...

Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.

BACKGROUND PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) patients can be used for initial staging and monitoring therapy response in bone marrow (BM) and peripheral blood (PB). PHOX2B has been identified as a sensitive and specific MRD marker; however, its expression varies between tumors. Therefore, a panel of markers could increase sensitivity. METHODS To ident...

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?

Minimal residual disease evaluation refers to a series of molecular and immunophenotypical techniques aimed at detecting submicroscopic disease after therapy. As such, its application in acute myeloid leukemia has greatly increased our ability to quantify treatment response, and to determine the chemosensitivity of the disease, as the final product of the drug schedule, dose intensity, biodistr...

Chemoprophylaxis in the prevention of Clostridium difficile infection: Still a ways to go.